Skip to search formSkip to main contentSkip to account menu

Sumanirole

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

U 95666E

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Antihyperalgesic effects of intrathecal perospirone in a rat model of neuropathic pain
2015
2015
Pramipexole protects dopaminergic neurons through paraplegin against 6-hydroxydopamine
The neurotransmitter dopamine (DA) regulates various physiological and psychological functions, such as movement, motivation… 
2013
2013
Research in the field of 1,2,3,4-tetrahydroquinoline derivative total synthesis of sumanirole synthetic approach to virantmycin and martinellic acid
Depuis quelques annees, nous nous interessons au developpement de nouvelles strategies permettant d’acceder a des structures de… 
Review
2008
Review
2008
Review: Nonergot dopamine agonists reduce symptoms in the restless legs syndrome but may be discontinued due to adverse events
Question Are nonergot dopamine agonists (NEDAs) effective and safe for the restless legs syndrome (RLS)? Review scope Articles… 
2007
2007
Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study.
2005
2005
The Effects of a Selective Dopamine D2 Receptor Agonist on Behavioral and Pathological Outcome in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Squirrel Monkeys
In this study, we investigated antiparkinsonian activity of the novel, highly selective dopamine D2 receptor agonist sumanirole… 
Review
2003
Review
2003
Sumanirole Pharmacia.
Sumanirole is a dopamine D2 agonist under development by Pharmacia Corp (formerly Pharmacia & Upjohn) for the treatment of… 
2002
2002
Development of a practical synthesis of sumanirole
Abstract A new synthesis of sumanirole that is being developed to treat Parkinson's disease is described. The basic skeleton is… 
2002
2002
Lack of Significant Drug Interactions for Sumanirole in Phase II Studies Using Population Pharmacokinetic Methods
  • 2002
  • Corpus ID: 98754895
2-selective dopamine receptor agonist that is in development for the treatment of Parkinson's disease (PD). Metabolism of… 
2002
2002
Differentiation of dyskinesia side effect in mptp treated monkeys treated with sumanirole and levodopa
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)